Pharmacists should reinforce that semaglutide remains highly effective but may produce less absolute weight loss than tirzepatide, owing to differing receptor profiles 14
PKA, Protein kinase A
Annual Costs (2025) Retail Pharmaceutical (Wegovy/Mounjaro as proxies): Without insurance: $12,000-16,800/year With insurance coverage: $1,200-3,600/year (copays) Retatrutide will likely price similarly when approved Research Peptide Suppliers: Maintenance dose (4mg weekly): $3,600-6,000/year Higher dose (8mg weekly): $7,200-12,000/year Requires self-sourcing from suppliers like Red Fox Peptides (third-party HPLC/MS testing, 98%+ purity verification, with delivery within 2-4 days for Canadian customers) Dose Reduction Strategies Many patients successfully maintain on lower doses than required for active weight loss: Lost weight on 12mg weekly
At the maintenance dose of 10 mg per week, one vial lasts exactly one week
In conclusion, the modifiable risk factors obesity, diabetes, and hypertension increase the risk of COVID-19related mortality in young and middle-aged patients to the level of risk observed in advanced age
Requires frequent injections (weekly or biweekly)
